Orthocell Limited appoints exclusive Australian distributor for Remplir

Orthocell Limited (ASX: OCC) announced the appointment of Device Technologies as its exclusive distributor of Remplir for peripheral nerve repair in Australia and New Zealand. Device Technologies will market and distribute Remplir for usage in the surgical repair of peripheral nerves all over Australia and New Zealand.  It will also be working on targeted promotion events, initiate sales, and grow the network of referring plastic and orthopedic surgeons.

The agreement has an early term of five years and allows Orthocell to enter into this strategic market with a rising acceptance of Australian Made, high-quality healthcare products. Orthocell is now well-placed to advance commercial traction with this product in Australia and to grow into the US, the largest global healthcare market in the world.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au